# Wednesday April 22, 2015

**Joint Workshop: EASL- ILC Viral Hepatitis Workshop**  
Hall C (Plenary)

**Chairs:**  
Jean-Michel Pawlotsky (France)  
Markus Peck-Radosavljevic (Austria)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Is HBV infection curable?</td>
</tr>
<tr>
<td>8:30</td>
<td>Challenge: the HCC epidemics in &quot;cured&quot; hepatitis patients</td>
</tr>
<tr>
<td>9:00</td>
<td>HCV treatment to PWID-results from the ACTIVATE trial</td>
</tr>
<tr>
<td>9:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:00</td>
<td>Management of patients with HCV-related advanced liver disease or in the peritransplant setting with new DAA-based therapies</td>
</tr>
<tr>
<td>10:30</td>
<td>Are hepatitis C medications too expensive?</td>
</tr>
</tbody>
</table>

**Joint Workshop: EASL-ICA**  
Strauss 1

**Chair:**  
Mauro Bernardi (Italy)  
Paolo Angeli (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Introduction</td>
</tr>
<tr>
<td>8:10</td>
<td>Microbiology of bacterial infections in cirrhosis; how has it changed over the last years?</td>
</tr>
<tr>
<td>8:30</td>
<td>The microbiome and bacterial translocation in cirrhosis</td>
</tr>
<tr>
<td>8:50</td>
<td>Non antibiotic prophylaxis of bacterial infections in cirrhosis; where we are and where we are going to?</td>
</tr>
<tr>
<td>9:10</td>
<td>Discussion</td>
</tr>
<tr>
<td>9:30</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:00</td>
<td>New protocols of empirical antibiotic treatment of bacterial infections in cirrhosis</td>
</tr>
<tr>
<td>10:20</td>
<td>The changing role of albumin in the management of patients with cirrhosis and bacterial infections: from plasma expander to immuneregulator and anti-inflammatory agent</td>
</tr>
<tr>
<td>10:40</td>
<td>Conclusions</td>
</tr>
<tr>
<td>10:40</td>
<td>Discussion</td>
</tr>
</tbody>
</table>
Joint Workshop: EASL- FLIP
Strauss 2

Chairs:
Cecilia Rodrigues (Portugal)
Vlad Ratziu (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:00</td>
<td><strong>Advances in Pathogenesis</strong></td>
</tr>
<tr>
<td>8:00 - 8:30</td>
<td>Mechanisms of NASH-related fibrogenesis: clues for individual variability</td>
</tr>
<tr>
<td></td>
<td>Fabio Marra (Italy)</td>
</tr>
<tr>
<td>8:30 - 8:50</td>
<td>Cholesterol toxicity and hepatic inflammation</td>
</tr>
<tr>
<td></td>
<td>Ronit Shiri-Sverdlov (Netherlands)</td>
</tr>
<tr>
<td>8:50 - 9:00</td>
<td>Discussion</td>
</tr>
<tr>
<td>9:00 - 9:30</td>
<td><strong>Advances in Diagnosis</strong></td>
</tr>
<tr>
<td>9:00 - 9:20</td>
<td>The FLIP algorithm and SAF score: a new histological classification in NAFLD</td>
</tr>
<tr>
<td></td>
<td>Pierre Bedossa (France)</td>
</tr>
<tr>
<td>9:20 - 9:30</td>
<td>Discussion</td>
</tr>
<tr>
<td>9:30 - 10:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:00 - 10:50</td>
<td><strong>Clinical Hotspots</strong></td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td>A critical review of the evidence linking diabetes and obesity to liver cancer</td>
</tr>
<tr>
<td></td>
<td>Hashem El-Serag (United States)</td>
</tr>
<tr>
<td>10:20 - 10:40</td>
<td>NASH in developing countries: the paradox of the Indian subcontinent</td>
</tr>
<tr>
<td></td>
<td>Abhijit Chowdhury (India)</td>
</tr>
<tr>
<td>10:40 - 10:50</td>
<td>Discussion</td>
</tr>
<tr>
<td>10:50 - 11:00</td>
<td>General Discussion and Closing Remarks</td>
</tr>
</tbody>
</table>

Post-Graduate Course: Liver Transplant
Organised by EASL-ILTS-ELITA-LICAGE

Strauss 3

Chairs:
John Klink (United Kingdom)
Richard Freeman (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 8:20</td>
<td>Acute on chronic liver disease: when is the patient too sick for transplant?</td>
</tr>
<tr>
<td></td>
<td>Henrik Petrowsky (Switzerland)</td>
</tr>
<tr>
<td>8:20 - 8:40</td>
<td>Hepatopulmonary syndrome and portopulmonary hypertension: when is the optimal timing for liver transplantation?</td>
</tr>
<tr>
<td></td>
<td>Susan Mandell (United States)</td>
</tr>
<tr>
<td>8:40 - 9:00</td>
<td>Severe acute alcoholic hepatitis non-responding to steroid therapy: when is it justified to transplant?</td>
</tr>
<tr>
<td></td>
<td>Philippe Mathurin (France)</td>
</tr>
<tr>
<td>9:00 - 9:20</td>
<td>Are there age limits for living or deceased donors or for recipients?</td>
</tr>
<tr>
<td></td>
<td>Juan Carlos Garcia Valdecasas (Spain)</td>
</tr>
<tr>
<td>9:20 - 9:30</td>
<td>Discussion</td>
</tr>
<tr>
<td>9:30 – 10:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10:00 - 10:20</td>
<td>How should candidates with previous history of non-hepatic malignancy be selected for liver transplantation: what is the risk for recurrence after liver transplant?</td>
</tr>
<tr>
<td></td>
<td>Federico Vilamil (Argentina)</td>
</tr>
</tbody>
</table>
10:20 - 10:40 Retransplant the non-compliant and compliant adolescents?  
Anil Dhawan (Argentina)

10:40 - 11:00 Discussion

11:00 - 11:30 Break

Chairs:  
Patrizia Burra (Italy)  
Paolo Muesian (United Kingdom)

11:30 - 11:50 Neo-adjuvant and adjuvant anti-HCV treatment and transplantation: have we solved the problem?  
Xavier Forns (Spain)

11:50 - 12:10 HCC and downstaging procedures: have the results of liver transplantation been improved?  
Vincenzo Mazaferro (Italy)

12:10 - 12:30 Selection and timing of liver transplantation for patients with drug and hepatotoxins induced liver injury  
Giacomo Germani (Italy)

12:30 - 12:50 Current status of liver transplantation in HIV infected recipients: long-term outcome  
Didier Samuel (France)

12:50 - 13:10 Morbidly obese patients: should they receive simultaneous liver transplantation and sleeve gastrectomy?  
Julie Heimbach (United States)

13:10 - 13:40 Ethics in donor living related liver transplantation: Eastern perspective  
Chao-Long Chen (Taiwan)

13:40 - 13:45 Discussion and Closing remarks

Joint Workshop: EASL-Public Health CAG

Lehar 1 & 2

Chairs:  
Alessio Aghemo (Italy)  
Angelos Hatzakis (Greece)

8:00 - 8:15 Efforts to estimate HBV prevalence and future trends  
Joerdis Ott (Switzerland)

8:15 - 8:30 HBV vaccination: A global success story and prospects for universal coverage  
Pierre van Damme (Belgium)

8:30 - 8:45 Modelling studies to assess the global burden of HCV in the next 20 years  
Homie Razavi (United States)

8:45 - 9:00 Current and future HCV burden in Egypt  
Imam Waked (Egypte)

9:00 - 9:15 Current and future HCV burden in Greece  
Vana Sypsa (Greece)

9:15 - 9:30 Current and future HCV burden in Germany  
Heiner Wedemeyer (Germany)

9:30 - 10:00 Coffee Break

10:00 - 10:15 Current and future options to treat high risk groups and difficult to treat patients: Chronic HBV  
Maurizia Brunetto (Italy)
10:15 - 10:30 Current and future options to treat high risk groups and difficult to treat patients: Chronic HCV
Jason Grebely (Australia)

10:30 - 10:45 Prospects for an effective HCV vaccine
Thomas Baumert (France)

10:45 - 11:00 Discussion

**EASL-ISHEN workshop: HE in the Out-patient Cirrhotic Patient**

**Lehar 3**

**Chair:**
Radha Krishan Dhiman (India)
Sara Montagnese (Italy)
George Papatheodoridis (Greece)

8:00 - 8:20 Impact/Burden of HE on the health system and society
Peter Jepsen (Denmark)

8:20 - 8:40 Covert HE: One disease or two. How to diagnose?
Sara Montagnese (Italy)

8:40 - 9:00 Minimal HE, quality of life and driving: practical recommendations
Jasmohan S. Bajaj (United States)

9:00 - 9:20 What is a good clinical measure of outcome in a cirrhotic patient with minimal HE?
Radha Krishan Dhiman (India)

9:20 - 9:30 Discussion

9:30 – 10:00 Coffee Break

10:00 - 10:20 Pathophysiological basis of HE in a patient with overt HE: Different to multiorgan failure?
Rajiv Jalan (United Kingdom)

10:20 - 10:40 Evidence based management of hospitalised HE patient. Report from a multidisciplinary Consensus meeting
Claire Francoz (France)

10:40 - 11:00 Issues with clinical trial design in studies of HE in the hospitalised cirrhotic patient
Oliviero Riggio (Italy)

**Joint Workshop: EASL-MSF-Prolifica-TAG**

**Lehar 4**

**Chairs:**
Laurent Castera (France)
Tracy Swan (United States)

8:00 - 8:20 HCV treatment access in LMICs: civil society activities
Karyn Kaplan (United States)

8:20 - 8:40 Access to treatment in Asia
Nicolas Durier (Thailand)

8:40 - 9:00 Access to HCV treatment in Ukraine and role of civil society
Ludmila Maistat (Ukraine)

9:00 - 9:30 Access to HBV and HCV diagnostics and treatments in RLS
Isabelle Andrieux-Meyer (Switzerland)

9:30 – 10:00 Coffee Break
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 - 10:30</td>
<td>HBV Prevention of mother to child transmission</td>
<td>Mark Thursz</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>HBV prevalence among HIV people in some MSF cohorts</td>
<td>Dmytro Donchuk</td>
<td>Belgium</td>
</tr>
</tbody>
</table>

**Joint Workshop: EASL-ILCA**

**Stolz 1**

**Chairs:**
- Helen Reeves (United Kingdom)
- Peter Galle (Germany)

- **8:00 - 8:30** Identification of biomarkers and candidates for targeted drug therapy  
  - Helen Reeves (United Kingdom)
- **8:30 - 9:00** HCC Staging Systems 2014 – Time for a change?  
  - Ronnie Poon (Hong Kong, China)
- **9:00 - 9:30** Current clinical landscape in systemic therapy  
  - Markus Wörns (Germany)
- **9:30 - 10:00** Coffee Break
- **10:00 - 10:30** Locoregional therapy: Patient selection, methods, response assessment  
  - Riccardo Lencioni (Italy)
- **10:30 - 11:00** Surgery at the borderline: extended resection, Tx beyond Milan  
  - Eric Vibert (France)

**Joint Workshop: EASL-Virtual Liver Network**

**Stolz 2**

**Chairs:**
- Frank Tacke (Germany)
- Steven Dooley (Germany)

- **8:00 - 8:20** LPS showcase of the VLN: Feedback and feedforward signaling loops in the LPS mediated acute phase response of the liver  
  - Johannes Bode (Germany)
- **8:20 - 8:50** LPS and cell-cell communication in inflammatory and fibrogenic responses of the liver  
  - Sophie Lotersztajn (France)
- **8:50 - 9:10** HGF showcase of the VLN: - Multi- (molecular-, cell-, tissue- and body-) scale, spatial & temporal model of HGF mediated liver regeneration  
  - Dirk Drasdo (Germany)
- **9:10 - 9:30** Discussion
- **9:30 – 10:00** Coffee Break
- **10:00 - 10:15** EGFR mediated crosstalk in liver injury and hepatocarcinogenesis  
  - Matias Avila (Spain)
- **10:15 - 10:30** Cell-cell communication in damage induced liver regeneration  
  - Robert Schwabe (United States)
- **10:30 - 10:45** Steatosis showcase of the VLN: Hedgehog as master regulator of liver lipid metabolism  
  - Madlen Matz-Soja (Germany)
- **10:45 - 11:00** Discussion
Joint Workshop: EASL-VALDIG
Schubert 2

Chairs:
Andrea de Gottardi (Switzerland)
Frank Lammert (Germany)

8:00 - 8:05 Introduction
Frank Lammert (Germany)

8:05 - 8:35 Liver histology in non-cirrhotic portal hypertension: several facets of the same disease?
Dominique Cazals-Hatem (France)

8:35 - 9:05 Extrahepatic portal vein obstruction and portal biliopathy
Yogesh Chawla (India)

9:05 - 9:30 Novel findings in portal vein thrombosis in cirrhotic patients
Juan Carlos Garcia-Pagan (Spain)

9:30 – 10:00 Coffee Break

10:00 - 10:30 Novel insights into the JAK2 signalling pathway: linking the V617F mutation with clotting abnormalities
Jonel Trebicka (Germany)

10:30 - 11:00 How imaging techniques may help clinicians in the management of splanchnic vein thrombosis today and tomorrow
Fabrizio Fanelli (Italy)

Joint Workshop: EASL-International PSC study group
Schubert 3

Chairs:
Cyriel Ponsioen (Netherlands)
Tom Karlsen (Norway)

8:00 - 8:30 A brief history of prognostic models and clinical trial end-points in PSC
Olivier Chazouillères (France)

8:30 - 9:00 Regulatory aspects of clinical trial end-point considerations
Elmer Schabel (Germany)

9:00 - 9:30 Does a PSC specific fibrosis biomarker profile exist?
Morten Karsdal (Denmark)

9:30 – 10:00 Coffee Break

10:00 - 10:30 End-point strategies for anti-fibrotics in NASH - lessons for PSC
Massimo Pinzani (United Kingdom)

10:30 - 11:00 Discussion
Joint Workshop: EASL-INHSU
Schubert 4

Chairs:
Cihan Yurdaydin (Turkey)
Olav Dalgard (Norway)

8:00 - 8:30  Somatic illness in PWID - the impact of liver disease
Kunt Boe Kielland (Norway)

8:30 - 9:00  Screening for fibrosis among PWID
Peer Brehm Christensen (Denmark)

9:00 - 9:30  HCV treatment to PWID - results from the ACTIVATE trial
Gregory Dore (Australia)

9:30 – 10:00  Coffee Break

10:00 - 10:30  Reinfection following SVR
Janke Schinkel (Netherlands)

10:30 - 11:00  Interventions to prevent HCV transmission
Sharon Hutchinson (United Kingdom)

Post Graduate Course - Metabolic liver disease
Hall D

Chairs:
Jean-François Dufour (Switzerland)
Vlad Ratziu (France)
Herbert Tilg (Austria)

Challenges in the Diagnosis of NASH
11:30 - 11:45  Q&A (QUESTIONS) case presentation
Felix Brunner (Switzerland)

11:45 - 12:05  Who should be screened for NASH?
Naga Chalasani (United States)

12:05 - 12:25  Histological classifications: how and when to trust the pathologist
Pierre Bedossa (France)

12:25 - 12:45  Non-invasive diagnosis of fibrosis in NAFLD: how reliable is it?
Leon Adams (Australia)

12:45 - 13:05  Pediatric NASH: is it different and should we look for it?
Valerio Nobili (Italy)

13:05 - 13:25  NASH in lean patients
Vincent Wong (Hong Kong, China)

13:25 - 13:30  Q&A (ANSWERS)

13:30 - 14:00  Lunch
NAFLD and Interactions with Insulin Resistance
14:00 - 14:15  Q&A (QUESTIONS) case presentation  
Pierre-Emmanuel Rautou (France)
14:15 - 14:35  Excessive body weight and risk of NASH: are all obese patients equal?  
Amalia Gastaldelli (Italy)
14:35 - 14:55  Insulin resistance: should we measure it and does it promote liver disease progression?  
Elisabetta Bugianesi (Italy)
14:55 - 15:15  Dysmetabolic hyperferritinemia  
Yves Deugnier (France)
15:15 - 15:35  Bariatric surgery: a cure for NASH?  
Carel Leroux (United Kingdom)
15:35 - 15:40  Q&A (ANSWERS)

Extrahepatic Complications of Liver Fat
16:00 - 16:15  Q&A (QUESTIONS) case presentation  
Fabio Nascimbeni (Italy)
16:15 - 16:35  Why does liver fat contribute to cardio-metabolic outcomes?  
Hannele Yki-Jarvinen (Finland)
16:35 - 16:55  NAFLD, pre-atherogenic lesions and cardiovascular events  
Sven Francque
16:55 - 17:15  Does steatosis place patients at risk for diabetes development and progression?  
Naveed Sattar (United Kingdom)
17:15 - 17:35  Current and future insulin sensitzers in the treatment of NASH?  
Vlad Ratziu (France)
17:35 - 17:40  Q&A ANSWERS

Basic Science Seminar - Liver Tumours
Hall C (Plenary)

Chairs:  
Maria Martinez-Chantar (Spain)  
Helen Reeves (United Kingdom)  
Lars Zender (Germany)

Introduction and aims  
Speaker: Helen Reeves (United Kingdom)

Hepatocellular Cancer Genomics  
Oncogenomics and identification of drivers of genetic hepatocarcinogenesis  
Speaker: Jessica Zucman Rossi (France)  
Fellow: Eric Letouzé (France)
11:35 - 11:45  Lecture  
Jessica Zucman Rossi (France)
11:45 - 11:55  Mutational signatures in liver cancer  
Eric Letouzé (France)
11:55 - 12:00  Discussion
Genome wide epigenomics in HCC  
Table 1: 
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>TBD</td>
<td>Lecture</td>
</tr>
<tr>
<td>12:10</td>
<td>Anna Martinez-Cardus (Spain)</td>
<td>Value of DNA methylation Alterations in Liver Cancer</td>
</tr>
<tr>
<td>12:20</td>
<td>TBD</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

Biomarkers for risk stratification emerging from genomic studies in HCC  
Table 1: 
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>Yujin Hoshida (United States)</td>
<td>Lecture</td>
</tr>
<tr>
<td>12:40</td>
<td>Anu Venkatesh (United States)</td>
<td>Molecular signature-based prognostic prediction in liver cirrhosis and HCC</td>
</tr>
<tr>
<td>12:50</td>
<td>Anu Venkatesh (United States)</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

Functional genomics leading to new therapeutic targets  
Table 1: 
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td>Lars Zender (Germany)</td>
<td>Lecture</td>
</tr>
<tr>
<td>13:10</td>
<td>Florian Heinzmann (Germany)</td>
<td>In vivo RNAi screening to dissect tumor suppressor networks in HCC</td>
</tr>
<tr>
<td>13:20</td>
<td>Florian Heinzmann (Germany)</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

Hepatocellular cancer - Signalling in the tumour microenvironment  
Signalling pathways in Hepatocarcinogenesis  
Table 1: 
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>Tom Luedde (Germany)</td>
<td>Lecture</td>
</tr>
<tr>
<td>14:10</td>
<td>Jérémy Gautheron (Germany)</td>
<td>Cell Death and Inflammation in Hepatocarcinogenesis</td>
</tr>
<tr>
<td>14:20</td>
<td>Jérémy Gautheron (Germany)</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

EGFR interaction in Hepatocarcinogenesis  
Table 1: 
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>Maria Sibilia (Austria)</td>
<td>Lecture</td>
</tr>
<tr>
<td>14:40</td>
<td>Karin Komposch (Austria)</td>
<td>Role of EGFR in liver fibrosis and cancer</td>
</tr>
<tr>
<td>14:50</td>
<td>Karin Komposch (Austria)</td>
<td>Discussion</td>
</tr>
</tbody>
</table>
### The contribution of post translational modification

**Speaker:** Maria Luz Martinez Chantar (Spain)  
**Fellow:** Teresa Cardoso Delgado (Spain)

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speaker/Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:00 - 15:10</td>
<td>Lecture</td>
<td>Maria Luz Martinez Chantar (Spain)</td>
</tr>
<tr>
<td>15:10 - 15:20</td>
<td>Neddylation as a metabolic therapeutic target in HCC</td>
<td>Teresa Cardoso Delgado (Spain)</td>
</tr>
<tr>
<td>15:20 - 15:30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

15:30 - 16:00 | Coffee Break |                                      |

### Hepatocellular cancer - a focus on metabolism

**Metabolic Reprogramming in Cancer**

**Speaker:** Antonio Moschetta (Italy)  
**Fellow:** Chiara Degirolamo (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speaker/Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:10</td>
<td>Lecture</td>
<td>Antonio Moschetta (Italy)</td>
</tr>
<tr>
<td>16:10 - 16:20</td>
<td>Hepatocellular Carcinoma and the Gut-Liver Axis: a focus on the FXR-FGF19 team</td>
<td>Chiara Degirolamo (Italy)</td>
</tr>
<tr>
<td>16:20 - 16:30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Lipid metabolism and HCC

**Speaker:** Stephan Herzig (Germany)  
**Fellow:** Mauricio Berriel Diaz (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speaker/Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:30 - 16:40</td>
<td>Lecture</td>
<td>Stephan Herzig (Germany)</td>
</tr>
<tr>
<td>16:40 - 16:50</td>
<td>Molecular links between fatty liver disease and HCC</td>
<td>Mauricio Berriel Diaz (Germany)</td>
</tr>
<tr>
<td>16:50 - 17:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Wnt and metabolism in HCC

**Speaker:** Sabine Colnot (France)  
**Fellow:** Angélique Gougelet (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
<th>Speaker/Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 17:10</td>
<td>Lecture</td>
<td>Sabine Colnot (France)</td>
</tr>
<tr>
<td>17:10 - 17:20</td>
<td>How beta-catenin reprograms the hepatocyte in liver cancer</td>
<td>Angélique Gougelet (France)</td>
</tr>
<tr>
<td>17:20 - 17:30</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>
Nurses and Associates Forum
Lehar 3

Chairs:
Michelle Clayton (United Kingdom)
Cristina Rivoltella (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 14:30</td>
<td>How to address the burden of liver disease in Europe</td>
<td>Dominique-Charles Valla (France)</td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td>Tackling fatty liver disease with lifestyle measures</td>
<td>Shira Zelber-Sagi (Israel)</td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td>Reviewing the educational needs of liver nurses</td>
<td>Jacqui Richmond (Australia)</td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td>Multi resistant organisms in liver transplantation: lessons learnt from practise</td>
<td>Enrica Capitoni (Italy)</td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td>Weight gain, overweight and obesity in solid organ transplantation: Need for action?</td>
<td>Sonja Beckmann (Switzerland)</td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td>Exploring the supportive care needs of people with advanced chronic liver disease</td>
<td>Barbara Kimbell (United Kingdom)</td>
</tr>
</tbody>
</table>

Closing

Major Sponsor Industry Satellite Symposium

18:00 - 19:30 | Please refer to the Industry Section
Thursday April 23, 2015

Industry Satellite Symposium

7:30 - 8:30 Please refer to the Industry Section

Post Graduate Course - Metabolic liver disease

Hall D

Chairs:
Jean-François Dufour (Switzerland)
Vlad Ratziu (France)
Herbert Tilg (Austria)

Carcinogenesis and NAFLD

8:30 - 8:45 Q&A (QUESTIONS) case presentation
Heinz Zoller (Austria)

8:45 - 9:05 Carcinogenesis and the spectrum of hepatic tumours in NASH
Augusto Villanueva (United Kingdom)

Jean-François Dufour (Switzerland)

9:25 - 9:45 Do inflammation networks trigger NASH and drive its progression?
Herbert Tilg (Austria)

9:45 - 10:05 Impact of lifestyle on NASH (inclusive on HCC)
Ingrid Hickman (Australia)

10:05 - 10:10 Q&A ANSWERS

10:10 - 10:30 Coffee Break

Progression of Liver Disease in NAFLD

10:30 - 10:45 Q&A (QUESTIONS) case presentation
Grace Dolman

10:45 - 11:05 Who are the NAFLD patients a risk of disease progression?
Chris Day (United Kingdom)

11:05 - 11:25 NAFLD diabetes and alcohol: is there a safe threshold?
Stefano Bellentani (Italy)

11:25 - 11:45 The course of cirrhotic NASH: how different is it from other cirrhoses?
Arun Sanyal (United States)

11:45 - 12:05 OLT for NASH
Didier Samuel (France)

12:05 - 12:10 Q&A ANSWERS

12:10 - 13:30 Lunch Break
Basic Science Seminar - Liver Tumours
Hall C (Plenary)

Chairs:
    Maria Martinez-Chantar (Spain)
    Helen Reeves (United Kingdom)
    Lars Zender (Germany)

Cellular Plasticity, stem cells and liver tumours
The cellular origins of liver tumours
Speaker: Thomas Longerich (Germany)
Fellow: Rosella Pellegrino (Germany)
8:30 - 8:40  Lecture
    Thomas Longerich (Germany)
8:40 - 8:50  Modes of MDM4 dysregulation in hepatocellular carcinoma
    Rosella Pellegrino (Germany)
8:50 - 9:00  Discussion

FGF Signalling in hepatocarcinogenesis
Chair: Lewis Roberts (United States)
Fellow: Renumathy Dhanasekaran (United States)
9:00 - 9:10  Lecture
    Lewis Roberts (United States)
9:10 - 9:20  Modulation of FGF Signaling by Heparan Sulfate Sulfatases in Liver Cancer
    Renumathy Dhanasekaran (United States)
9:20 - 9:30  Discussion

Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types
Speaker: Snorri Thorgeirson (United States)
Fellow: Jens Marquardt (Germany)
9:30 - 9:40  Lecture
    Snorri Thorgeirson (United States)
9:40 - 9:50  Targeting of "stemness" as a promising therapeutic strategy in liver cancer
    Jens Marquardt (Germany)
9:50 - 10:00  Discussion

10:00 - 10:30  Coffee Break

Microenvironment and therapy
The inflammatory response and its consequences - can we intervene?
Speaker: Derek Mann (United Kingdom)
Fellow: Caroline Wilson (United Kingdom)
10:30 - 10:40  Lecture
    Derek Mann (United Kingdom)
10:40 - 10:50  The role of neutrophils in HCC
    Caroline Wilson (United Kingdom)
10:50 - 11:00  Discussion
### Oncolytic viral therapy

**Speaker:** Oliver Ebert (Germany)  
**Fellow:** Jennifer Altomonte (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>Lecture</td>
</tr>
<tr>
<td>11:10</td>
<td>Oliver Ebert (Germany)</td>
</tr>
<tr>
<td>11:10</td>
<td>Targeting, delivery and imaging of oncolytic virotherapeutics</td>
</tr>
<tr>
<td>11:20</td>
<td>Jennifer Altomonte (Germany)</td>
</tr>
<tr>
<td>11:30</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

**Immunotherapy for HCC?**

**Speaker:** David Adams (United Kingdom)  
**Fellow:** Ka-Kit Li (United Kingdom)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Lecture</td>
</tr>
<tr>
<td>12:00</td>
<td>Challenges and Opportunities in liver disease in the EU</td>
</tr>
<tr>
<td>12:15</td>
<td>Opportunities for Liver Disease Research &amp; Collaboration in Horizon 2020</td>
</tr>
<tr>
<td>12:30</td>
<td>Opportunities for collaboration in the EU Health Programme 2014-2020</td>
</tr>
<tr>
<td>12:45</td>
<td>The role of the European Parliament in promoting liver health</td>
</tr>
<tr>
<td>13:00</td>
<td>The view from the Member States</td>
</tr>
<tr>
<td>13:15</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

### EU and Impact on General Health

**Strauss 3**

**Chairs:**  
Laurent Castera (France)  
Liliana Gheorghe (Romania)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Challenges and Opportunities in liver disease in the EU</td>
</tr>
<tr>
<td>12:15</td>
<td>Opportunities for Liver Disease Research &amp; Collaboration in Horizon 2020</td>
</tr>
<tr>
<td>12:30</td>
<td>Opportunities for collaboration in the EU Health Programme 2014-2020</td>
</tr>
<tr>
<td>12:45</td>
<td>The role of the European Parliament in promoting liver health</td>
</tr>
<tr>
<td>13:00</td>
<td>The view from the Member States</td>
</tr>
<tr>
<td>13:15</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

### Joint Workshop: EASL-KASL

**Lehar 1 & 2**

**Chairs:**  
TBD  
TBD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>TBD</td>
</tr>
<tr>
<td>13:30</td>
<td>TBD</td>
</tr>
</tbody>
</table>
Fellowship and Registry Grant Presentations
Lehar 4

Chairs:
TBC
TBC

12:00 - 12:15 Fellowship Presentation 1
12:15 - 12:30 Fellowship Presentation 2
12:30 - 12:45 Fellowship Presentation 3
12:45 - 13:00 Fellowship Presentation 4
13:00 - 13:10 Registry Grant - PLD Registry
Joost Ph Drenth (Netherlands)
13:10 - 13:20 Registry Grant - Prospective European Drug-Induced Liver Injury Registry (Pro-Euro-DILI Registry)
Raul Jesús Andrade (Spain)
13:20 - 13:30 Registry Grant - Hepatitis delta international network
Heiner Wedemeyer (Germany)

ePoster Oral Sessions
Hall B (ePoster Area)

12:00 – 13:00
Oral ePoster 1 | HBV | Ulus Akarca (Turkey)
Oral ePoster 2 | HCC | Tom Luedde (Germany)
Oral ePoster 3 | NASH | Philip Newsome (United Kingdom)
Oral ePoster 4 | Non-invasive assessment of liver disease | Emmanuel Tsochatzis (United Kingdom)

General Session 1 & Opening
Hall D

Chair:
Serge Erlinger (France)
Markus Peck-Radosavljevic (Austria)

13:30 - 14:00 Opening Ceremony

14:00 - 14:15 Abstract G01: LIRAGLUTIDE IS EFFECTIVE IN THE HISTOLOGICAL CLEARANCE OF NON-ALCOHOLIC STEATOHEPATITIS IN A MULTICENTRE, DOUBLE-BLINDED, RANDOMISED, PLACEBO-CONTROLLED PHASE II TRIAL
Matthew J. Armstrong (United Kingdom)

14:15 - 14:30 Abstract G02: LEDIPASVIR/SOFOSBUVIR WITH RIBAVIRIN IS SAFE AND EFFICACIOUS IN DECOMPENSATED AND POST LIVER TRANSPLANTATION PATIENTS WITH HCV INFECTION: PRELIMINARY RESULTS OF THE PROSPECTIVE SOLAR 2 TRIAL
Michael Manns (Germany)

14:30 - 14:45 Abstract G03: RIFAXIMIN AND PROPRANOLOL COMBINATION THERAPY IS MORE
EFFECTIVE THAN PROPRANOLOL MONOTHERAPY IN THE HEPATIC VENOUS PRESSURE GRADIENT RESPONSE AND PROPRANOLOL DOSE REDUCTION – A PILOT STUDY
Soon Koo Baik (Korea, South)

14:45 - 15:00
Abstract G04: ENGINEERED HBV-SPECIFIC T CELLS: DISENTANGLING ANTIVIRAL FROM KILLING CAPACITY
Sarene Koh (Singapore)

15:00 - 15:15
Abstract G05: EXOME SEQUENCING OF 243 LIVER TUMORS IDENTIFIES NEW MUTATIONAL SIGNATURES AND POTENTIAL THERAPEUTIC TARGETS
Kornelius Schulze (Germany)

15:15 - 15:30
Abstract G06: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF TSU-68 (ORANTINIB) COMBINED WITH TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
Joong-Won Park (Korea, South)

Parallel Session: Viral Hepatitis C therapy
Hall D

Chair: Alessio Aghemo (Italy)
Maria Buti (Spain)

16:00 - 16:15
Abstract O001: C-SALVAGE: GRAZOPREVIR (GZR; MK-5172), ELBASVIR (EBR; MK-8742) AND RIBAVIRIN (RBV) FOR CHRONIC HCV-GENOTYPE 1 (GT1) INFECTION AFTER FAILURE OF DIRECT-ACTING ANTIVIRAL (DAA) THERAPY
Xavier Forns (Spain)

16:15 - 16:30
Abstract O002: A SINGLE TABLET REGIMEN OF LEDIPASVIR/SOFOSBUVIR FOR 12 WEEKS IN HCV GENOTYPE 1 OR 4 INFECTED PATIENTS WITH HIV-1 CO-INFECTION: THE PHASE 3 ION-4 STUDY
Curtis Cooper (Canada)

16:30 - 16:45
Abstract O003: CAN HEPATITIS C TREATMENT BE SAFELY DELAYED?: EVIDENCE FROM THE VETERANS ADMINISTRATION HEALTHCARE SYSTEM
Jeffrey S. Mc Combs (United States)

16:45 - 17:00
Abstract O004: ON-TREATMENT VIROLOGIC RESPONSE AND TOLERABILITY OF SIMEPREVIR, DACLATASVIR AND RIBAVIRIN IN PATIENTS WITH RECURRENT HEPATITIS C VIRUS GENOTYPE 1B INFECTION AFTER ORTHOTOPIC LIVER TRANSPLANTATION (OLT): INTERIM DATA FROM THE PHASE II SATURN STUDY
Xavier Forns (Spain)

17:00 - 17:15
Abstract O005: RETREATMENT OF PATIENTS WHO FAILED 8 OR 12 WEEKS OF LEDIPASVIR/SOFOSBUVIR-BASED REGIMENS WITH LEDIPASVIR/SOFOSBUVIR FOR 24 WEEKS
Eric Lawitz (United States)

17:15 - 17:30
Abstract O006: C-SWIFT: GRAZOPREVIR/ELBASVIR + SOFOSBUVIR IN CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12 WEEKS
Fred Poordad (United States)

17:30 - 17:45
Abstract O007: ALL ORAL HCV THERAPY IS SAFE AND EFFECTIVE IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: INTERIM REPORT FROM THE HCV-TARGET REAL WORLD EXPERIENCE
Presenter: Rajender Reddy (United States)
Abstract O008: EFFICACY AND SAFETY OF GRAZOPREVIR AND ELBASVIR IN HEPATITIS C GENOTYPE 1–INFECTED PATIENTS WITH CHILD-PUGH CLASS B CIRRHOSIS (C-SALT PART A)
Ira M. Jacobson (United States)

Parallel Session: General Viral Hepatitis
Hall C (Plenary)

Chair:
Massimo Levrero (Italy)
Daniel Shouval (Israel)

16:00 - 16:15 Abstract O009: A PROSPECTIVE STUDY OF HEPATITIS B REACTIVATION IN PATIENTS WITH PRIOR HBV EXPOSURE UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION: REACTIVATION ASSOCIATION WITH GRAFT-VERSUS-HOST DISEASE
Wai-Kay Seto (Honduras)

16:15 - 16:30 Abstract O010: T AND B CELL RESPONSES AND PREVIOUS EXPOSURE TO HEPATITIS B VIRUS IN “ANTI-HBC ALONE” PATIENTS
Nasser Semmo (Germany)

16:30 - 16:45 Abstract O011: A NATIONWIDE SURVEY OF HEPATITIS E VIRUS INFECTION IN LIVER TRANSPLANT RECIPIENTS IN JAPAN
Presenter: Yukio Oshiro (Japan)

16:45 - 17:00 Abstract O012: HEPATITIS DELTA VIRUS CAN SURVIVE LIVER REGENERATION AND IS AMPLIFIED THROUGH HUMAN CELL DIVISION BOTH IN VITRO AND IN VIVO
Katja Giersch (Germany)

17:00 - 17:15 Abstract O013: EVALUATION OF HDV QUANTIFICATION ASSAYS WORLDWIDE: RESULTS OF THE FIRST HDV INTERNATIONAL QUALITY CONTROL STUDY
Frederic Le Gal (France)

17:15 - 17:30 Abstract O014: A TARGETED RNAI SCREEN USING A HIGH-THROUGHPUT INFECTIOUS MODEL SYSTEM UNCOVERS GLYPICAN GPC5 AS A HOST FACTOR FOR HEPATITIS B AND D VIRUS ENTRY
Eloi R. Verrier (France)

17:30 - 17:45 Abstract O015: QUANTITATIVE MEASUREMENTS OF MUTATIONS IN BASAL CORE PROMOTOR REGION SUGGEST A LOSS OF IMMUNE TOLERANCE IN HBEAG POSITIVE CHRONIC HEPATITIS B INFECTIONS
Gillian Rosenberg (Australia)

17:45 - 18:00 Abstract O016: HEPATITIS B SURFACE ANTIGEN AND DNA LEVELS CAN IDENTIFY INACTIVE CARRIERS AND PREDICT LOWER RISK FOR HEPATOCELLULAR CARCINOMA AND CIRRHOSIS AMONG GENOTYPE B AND C CHRONIC HEPATITIS B CARRIERS
Jessica Liu (Taiwan)

Parallel Session: Non-invasive marker of liver disease Management
Strauss 1

Chair:
Mireen Friedrich-Rust (Germany)
Massimo Pinzani (United Kingdom)
16:00 - 16:15 Abstract O017: EFFECTIVENESS OF TREATMENT INITIATION BASED ON FIBROSIS STAGE ASSESSED BY METHODS OF FIBROSIS DIAGNOSIS IN TERMS OF 5-YEAR INCIDENCE OF MORBI-MORTALITY Sylvie Deuffic-Burban (France)

16:15 - 16:30 Abstract O017A: NON-INVASIVE TOOLS AND RISK OF VARICES AND CLINICALLY SIGNIFICANT PORTAL HYPERTENSION IN COMPENSATED CIRRHOSIS: THE "ANTICIPATE" STUDY Juan G. Abraldes (Canada)

16:30 - 16:45 Abstract O018: 2D-SHEAR WAVE ELASTOGRAPHY IS EQUIVALENT OR SUPERIOR TO TRANSIENT ELASTOGRAPHY FOR LIVER FIBROSIS ASSESSMENT: RESULTS FROM AN INDIVIDUAL PATIENT DATA BASED META-ANALYSIS Eva Herrmann (Germany)

16:45 - 17:00 Abstract O019: THE VALUE OF DIFFERENT NON-INVASIVE TESTS FOR PREDICTING THE PRESENCE OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AND ESOPHAGEAL VARICES IN CIRRHOTIC PATIENTS Simona Bota (Austria)

17:00 - 17:15 Abstract O020: MAGNETIC RESONANCE ELASTOGRAPHY IS SUPERIOR TO CLINICAL PREDICTION MODELS FOR DETERMINATION OF ADVANCED FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A PROSPECTIVE STUDY Jeffrey Y. Cui (United States)

17:15 - 17:30 Abstract O021: NON-INVASIVE SCREENING OF LARGE ESOPHAGEAL VARICES USING ENDOSCOPIC CAPSULE AND/OR LIVER FIBROSIS TESTS Paul Cales (France)

17:30 - 17:45 Abstract O022: THE UK-PBC RISK SCORE: DERIVATION AND VALIDATION OF A RISK SCORE TO PREDICT LIVER EVENTS IN THE UK-PBC RESEARCH COHORT Marco Carbone (United Kingdom)

17:45 - 18:00 Abstract O023: REPEATED MEASUREMENT OF NON-INVASIVE FIBROSIS MARKERS TO ASSESS HEPATITIS C PROGRESSION AND CLINICAL OUTCOMES Sabela Lens (Spain)

Parallel Session: Fatty liver disease: Clinical

Strauss 3

Chair:
Helena Cortez-Pinto (Portugal)
Giulio Marchesini (Italy)

16:00 - 16:15 Abstract O040: HERITABILITY OF HEPATIC FIBROSIS AND HEPATIC STEATOSIS, AND THEIR SHARED GENE EFFECTS WITH METABOLIC TRAITS IN NAFLD: A PROSPECTIVE TWIN STUDY Rohit Loomba (United States)

16:15 - 16:30 Abstract O041: INCREASING ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES: DATA FROM SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS (SEER)-MEDICARE REGISTRIES (2004-2009) Zobair Younossi (United States)

16:30 - 16:45 Abstract O042: WEIGHT LOSS INTENSITY IS STRONGLY ASSOCIATED TO IMPROVEMENT OF HISTOLOGICAL PARAMETERS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AFTER 52 WEEKS OF LIFESTYLE MODIFICATION Eduardo Vilar-Gomez (Spain)
Abstract O043: THE FNDC5 RS3480 IS PROTECTIVE ON THE STEATOSIS AND FIBROSIS IN PATIENTS WITH NAFLD
Rodolphe Anty (France)

Abstract O044: DISTINCT FECAL AND PLASMA BILE ACID METABOLOME OF MICROBIAL ORIGIN CHARACTERIZES HUMAN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
Puneet Puri (United States)

Abstract O045: BIOACTIVE LIPIDS IN THE HUMAN LIVER IN 'COMMON NAFLD' AND 'PNPLA3 NAFLD'
Panu Luukkonen (Finland)

Abstract O046: SHORT-TERM VITAMIN D SUPPLEMENTATION IMPROVES HEPATIC STEATOSIS AS QUANTIFIED BY CONTROLLED ATTENUATION PARAMETER (CAP)
Caroline S. Stokes (Germany)

Abstract O047: REMOGLIFLOZIN ETABONATE REDUCES INSULIN RESISTANCE AND LIVER FUNCTION ENZYMES: ROLE FOR TREATMENT OF NASH.
Wiliam Wilkison (United States)

Parallel Session: Alcohol and DILI
Lehar 1 & 2

Chair: Frank Tacke (Germany)
Christophe Moreno

Abstract O032: STEROID THERAPY DIFFERENTIALLY ALTERS GUT MICROBIOTA COMPOSITION IN SEVERE ALCOHOLIC HEPATITIS
Shvetank Sharma (India)

Abstract O033: CCR2+ INFILTRATING MONOCYTES PROMOTE ACETAMINOPHEN-INDUCED ACUTE LIVER INJURY - THERAPEUTIC IMPLICATIONS OF INHIBITING CCR2 AND CCL2
Oliver Krenkel (Germany)

Abstract O034: FREQUENCY AND FUNCTION OF ANTI-BACTERIAL MAIT CELLS ARE SIGNIFICANTLY IMPAIRED IN ADVANCED ALCOHOLIC LIVER DISEASE.
Antonio Riva (United Kingdom)

Abstract O035: CCR9 AND CCL25 ARE EARLY PRO-INFLAMMATORY MEDIATORS IN ACUTE LIVER INJURY
Richard Parker (United Kingdom)

Abstract O036: OVEREXPRESSION OF C-MYC IN HEPATOCYTES PROMOTES INITIATION AND PROGRESSION OF ALCOHOLIC LIVER DISEASE
Yulia A. Nevzorova (Germany)

Abstract O037: MACROPHAGE AUTOPHAGY MEDIATED THE BENEFICIAL EFFECTS OF CANNABINOID RECEPTOR 2 IN ALCOHOLIC LIVER DISEASE
Fatima TEIXEIRA-CLERC (France)

Abstract O038: INVESTIGATING PARACETAMOL TOXICITY IN HEPARG-BASED 3D HUMAN HEPATIC ORGANTOTYPIC MODELS WITH NON-INVASIVE OPTICAL COHERENCE PHASE MICROSCOPY (OCPM)
Leonard J. Nelson (United Kingdom)

Abstract O039: CIRCULATING EXTRACELLULAR VESICLES WITH SPECIFIC PROTEOME ARE NOVEL BIOMARKERS AND THERAPEUTIC TARGETS FOR ALCOHOLIC LIVER DISEASE
Akiko Eguchi (United States)
Parallel Session: Liver immunology
Stolz 1

Chair:
Nasser Semmo (Switzerland)
Heiner Wedemeyer (Germany)

16:00 - 16:15 Abstract O024: CYCLOPHILIN AND NS5A INHIBITORS, BUT NOT OTHER ANTI-HCV AGENTS, PRECLUDE HCV-MEDIATED FORMATION OF DOUBLE MEMBRANE VESICLE VIRAL FACTORIES
Philippe Gallay (United States)

16:15 - 16:30 Abstract O025: ROLE OF CX3CL1-CX3CR1 AXIS FOR LIVER DENDRITIC CELL MATURATION IN HOMEOSTASIS AND INFLAMMATION.
Salvatore Sutti (Italy)

16:30 - 16:45 Abstract O026: CD4+ INTRAHEPATIC LYMPHOCYTES DRIVE LIVER INFLAMMATION VIA IMPAIRED REGULATORY PATHWAYS IN A MURINE MODEL OF CROHN’S-LIKE ILEITIS
Sara Omenetti (United States)

16:45 - 17:00 Abstract O027: THE EXPRESSION OF TUMOR SUPPRESSOR PTPRD IS DOWN-REGULATED IN THE LIVER OF PATIENTS WITH HCV INFECTION AND IN TUMOR LESIONS OF PATIENTS WITH HEPATOCELLULAR CARCINOMA
Nicolaas Van Renne (France)

17:00 - 17:15 Abstract O028: CROSS-TALK BETWEEN IL13 AND HEDGEHOG PATHWAYS CONTRIBUTES TO SCHISTOSOMIASIS MANSONI FIBROSIS
Thiago De Almeida Pereira (Brazil)

17:15 - 17:30 Abstract O029: HCV TRIGGERS WNT PARACRINE SIGNALLING THAT MODULATES METABOLIC LIVER ZONATION
Urszula Hibner (France)

17:30 - 17:45 Abstract O030: PRO-APOPTOTIC TNF RECEPTOR SIGNALING IS THE RESULT OF A NOVEL INNATE IMMUNE SENSING PATHWAY THAT DETERMINES CELL DEATH IN VIRUS-INFECTED HEPATOCYTES
Dirk Wohlleber (Germany)

17:45 - 18:00 Abstract O031: TG1050, A NOVEL IMMUNOTHERAPEUTIC TO TREAT CHRONIC HEPATITIS B, CAN CONTROL HBsAG AND PROVOKE HBsAG SEROCONVERSION IN HBV-PERSISTENT MOUSE MODELS
Perrine Martin (France)

EASL - ESGAR Joint Workshop
Lehar 4

16:00 - 18:00
Abdominal Sonography Course- Beginners
Lehar 3

Tutors:
Robert de Knecht (Netherlands)
Michael Gebel (Germany)
Andrei Potthoff (Germany)
Dave Sprengers (Netherlands)
Pavel Taimr (Netherlands)
Christoph Terkamp (Germany)

18:30 – 20:00

Major Sponsor Industry Satellite Symposium

18:30 - 20:00 | Please refer to the Industry Section
Friday, April 24, 2015

**Early Morning Workshops**

**Managing HCV patients with decompensated cirrhosis**

Hall C (Plenary)

Moderators:
- Kosh Agarwal (United Kingdom)
- Paolo Caraceni (Italy)

7:30 - 8:30

**Viral hepatitis form a payer-perspective**

Strauss 1

Moderators:
- Robert Saureman (Austria)
- TBD

7:30 - 8:30

**Finite Treatment of Chronic Hepatitis B**

Strauss 2

Moderators:
- Maria Buti (Spain)
- Milan Sonneveld (Netherlands)

7:30 - 8:30

**Alcohol & Nonalcoholic Steatohepatitis (NASH) – important challenge for the Public health**

Strauss 3

Moderators:
- Nick Sheron (United Kingdom)
- Mira Kojouharova (Bulgaria)

7:30 - 8:30

**Endpoints for antifibrotic trials: what does it take to be a game changer?**

Lehar 1 & 2

Moderators:
- Veronica Miller (United States)
- Detlef Schuppan (Germany)

7:30 - 8:30
Clinical Use of HBsAg quantification
Lehar 3

Moderators:
George Papatheodoridis (Greece)
Jörg Petersen (Germany)

7:30 - 8:30

Regression of fibrosis/cirrhosis: clinical implications
Lehar 4

Moderators:
Vincent Mallet (France)
Francesco Paolo Russo (Italy)

7:30 - 8:30

IFN-free regimens in the OLT setting
Stolz 1

Moderators:
Stefano Fagiuoli (Italy)
Xavier Forns (Spain)

7:30 - 8:30

Novel treatments in autoimmune liver disease
Stolz 2

Moderators:
Gideon Hirschfield (United Kingdom)
Christoph Schramm (Germany)

7:30 - 8:30

Selection of patients for TACE
Schubert 1

Moderators:
Joong-Won Park (Korea, South)
Wolfgang Sieghart (Austria)

7:30 - 8:30
**Optimal Management of IFN containing regimens**

**Schubert 2**

**Moderators:**
- José Luis Calleja (Spain)
- Maria Grazia Rumi (Italy)

7:30 - 8:30

**HEV in immunocompromised patients**

**Schubert 3**

**Moderators:**
- Harry Dalton (United Kingdom)
- Stanislas Pol (France)

7:30 - 8:30

**Selecting patients for artificial liver support**

**Schubert 4**

**Moderators:**
- Helena Isoniemi (Finland)
- Didier Samuel (France)

7:30 - 8:30

**Non-coding RNAs in liver pathophysiology**

**Schubert 5**

**Moderators:**
- Christoph Roderburg (Germany)
- Chiara Braconi (United Kingdom)

7:30 - 8:30

**Controversies in the diagnosis of HCC**

**Schubert 6**

**Moderators:**
- Alejandro Forner (Spain)
- Fabio Piscaglia (Italy)

7:30 - 8:30
General Session 2 & Award 1
Hall D

Chairs:
Laurent Castera (France)
Gyongyi Szabo (United States)

08:30 - 08:45 Abstract G07: THE PHASE 3 C-EDGE TREATMENT-NAÏVE (TN) STUDY OF A 12-WEEK ORAL REGIMEN OF GRAZOPREVIR (GZR, MK-5172)/ELBASVIR (EBR, MK-8742) IN PATIENTS WITH CHRONIC HCV GENOTYPE (GT) 1, 4, OR 6 INFECTION
Stefan Zeuzem (Germany)

08:45 - 09:00 Abstract G11: MICROBIAL TRANSLOCATION IN LIVER FIBROSIS INDUCES CHRONIC IFNAR SIGNALING THAT IMPAIRS INNATE IMMUNITY AGAINST BACTERIAL INFECTION
Zeinab Abdullah (Germany)

09:00 - 09:15 Abstract G09: TARGETING A HOST-CELL ENTRY FACTOR BARRICADES ANTIVIRAL RESISTANT HCV VARIANTS FROM ON-THERAPY BREAKTHROUGH IN HUMAN-LIVER MICE.
Philip Meuleman (Belgium)

09:15 Award Ceremony I

09:45 - 10:00 Abstract G10: MITOCHONDRIAL-TARGETED ANTIOXIDANT MITOQUINONE REDUCES PORTAL HYPERTENSION IN CCL4-CIRRHOTIC RATS BY DECREASING INTRAHEPATIC RESISTANCE.
Marina Vilaseca Barceló (Spain)

10:00 - 10:15 Abstract G08: INCIDENCE OF HEPATOCELLULAR CARCINOMA (HCC) AND COMPLICATIONS IN ALCOHOLIC COMPENSATED CIRRHOSIS. PRELIMINARY RESULTS OF A MULTICENTER PROSPECTIVE FRENCH AND BELGE COHORT (INCA CIRRAL)
Nathalie Ganne (France)

Jake P. Mann (United Kingdom)

J.P. Benhamou State of the Art Session
Hall D

Antonello Pietrangelo (Italy)

10:30 - 11:00 Iron and the liver…of pathogens, metabolic adaptation and human disease
Grand Rounds: Viral Hepatitis
Hall D

Chair: Fabien Zoulim (France)

11:30 - 12:00  Hepatitis C: IFN-free therapy for the rescue of a cirrhotic patient who failed protease inhibitor based triple therapy
Case Presentation: Kerstin Hartig-Lavie (France)
Case Discussion: François Bailly (France)

12:00 - 12:30  Hepatitis B: Long-term antiviral therapy of chronic hepatitis B: management of resistance and side effects
Case Presentation: Fanny Lebossé (France)
Case Discussion: François Bailly (France)

Grand Rounds: Complications of end-stage Liver Disease and link with liver transplantation
Hall C (Plenary)

Chair: Frederik Nevens (Belgium)

11:30 - 12:00  HCC and the concept of downstaging and bridging
Case Presentation: Jeroen Dekervel (Belgium)
Case Discussion: Chris Verslype (Belgium)

12:00 - 12:30  Refractory hepatic encephalopathy and indications for interventional radiology
Case Presentation: Len Verbeke (Belgium)
Case Discussion: Wim Laleman (Belgium)

Grand Rounds: Liver transplantation – new challenges in an aging population
Strauss 1

Chair: Christian Trautwein (Germany)

11:30  Introduction
Christian Trautwein (Germany)
Case 1
Tom Luedde (Germany)

Case 2
Daniela Kroy (Germany)

12:30  Conclusions
Frank Tacke (Germany)
Grand Rounds: Cholangiopathies: from basic to clinic

Strauss 2

Chair:
Domenico Alvaro (Italy)

11:30 - 12:00 Case 1: A challenging case of PSC
Vincenzo Cardinale (Italy)
Andrea Laghi (Italy)

12:00 - 12:30 Case 2: Cholangiocarcinoma, a cancer in search of the right classification
Vincenzo Cardinale (Italy)
Guido Carpino (Italy)

Grand Rounds: Basic Science - in vivo Imaging

Stolz 1

Chair:
Paul Kubes (Canada)

11:30 - 11:50 How to image the liver and the pros and cons of spinning disk versus two photon microscopy
Craig Jenne (Canada)

11:50 - 12:10 Spinning disk imaging liver disease
Paul Kubes (Canada)

12:10 - 12:30 Imaging liver viral infections using two photon
Matteo Iannacone (Italy)

Young Investigator Seminar - Liver Cell Death

Lehar 1 & 2

Chairs:
Cecilia Rodrigues (Portugal)
Femke Heindryckx (Sweden)

11:30 - 11:50 Type of cell deaths
Patrice Codogno (France)

11:50 - 12:10 Cell death in different liver diseases
Jose Fernandez Checa (Spain)

12:10 - 12:30 Biomarkers of cell death in liver
Heike Bantel (Germany)

Endoscopy and Liver Vein Catheter Live Session

Strauss 3

Moderators:
Andres Cardenas (Spain)
Arnulf Ferlitsch (Austria)
Roberto de Francis (Italy)

11:30 - 14:30
ePoster Oral Sessions
Hall B (ePoster Area)

12:30 – 13:30
Oral ePoster 1 | HCV | Markus Cornberg (Germany)
Oral ePoster 2 | Complication of cirrhosis | Thomas Reiberger (Austria)
Oral ePoster 3 | Genetic and metabolic liver disease | Jose Fernandez Checa (Spain)
Oral ePoster 4 | Alcohol | Alexandre Louvet (France)

Clinical Symposium - Towards HCV eradication
Hall D

Chair: Antonio Craxi (Italy)

14:00 - 14:05 | Introduction | Antonio Craxi (Italy)
14:05 - 14:25 | HCV screening strategies in a changing scenario | Angelos Hatzakis (Greece)
14:25 - 14:45 | Cure to eradicate | Alfredo Alberti (Italy)
14:45 - 15:05 | Vaccinate to eradicate | Jake Liang (United States)
15:05 - 15:30 | General Discussion |

Basic Symposium - Hepatokines and their role in energy homeostasis
Hall C (Plenary)

Chair: Catherine Postic (France)

14:00 - 14:30 | The role of hepatokines in metabolism : the example of Fetuin | Norbert Stefan (Germany)
14:30 - 15:00 | PTEN signaling in metabolic liver diseases and crosstalk to peripheral organs through the release of hepatokines | Michelangelo Foti (Switzerland)
15:00 - 15:30 | Interplay between FGF21 and insulin action in the liver regulates metabolism | Brice Emmanuelli (Denmark)
### Translational Workshop - Liver mitochondria: plastic mediators of organ and integrated body responses

**Strauss 1**

**Chair:** Luca Scorano (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>The role of the mitochondrial Mtch1 in hepatic metabolism</td>
<td>Carlos Lopez-Otin (Spain)</td>
</tr>
<tr>
<td>14:30</td>
<td>The role of mitochondria-derived vesicles in hepatic carcinogenesis</td>
<td>Heidi McBride (Canada)</td>
</tr>
<tr>
<td>15:00</td>
<td>Mitochondrial plasticity in the fasting-fed liver</td>
<td>Luca Pellegrini (Canada)</td>
</tr>
</tbody>
</table>

### Clinical Symposium - PBC

**Strauss 2**

**Chair:** Michael Trauner (Austria)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>Introduction</td>
<td>Michael Trauner (Austria)</td>
</tr>
<tr>
<td>14:05</td>
<td>Risk stratification in PBC</td>
<td>Christophe Corpechot (France)</td>
</tr>
<tr>
<td>14:30</td>
<td>Bile acid-targeted therapy of PBC: UDCA and beyond (FXR, PPAR)</td>
<td>Ulrich Beuers (Netherlands)</td>
</tr>
<tr>
<td>14:55</td>
<td>Should we treat PBC as an autoimmune disease?</td>
<td>Gideon Hirschfield (United Kingdom)</td>
</tr>
<tr>
<td>15:20</td>
<td>General Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Parallel Session: Viral Hepatitis C: Clinical

**Hall D**

**Chair:** Thomas Berg (Germany)

Stanislas Pol (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>LEDIPASVIR/SOFOSBUVIR TREATMENT RESULTS IN HIGH SVR RATES IN PATIENTS WITH CHRONIC GENOTYPE 4 AND 5 HCV INFECTION</td>
<td>Armand Abergel (France)</td>
</tr>
<tr>
<td>16:15</td>
<td>LONG-TERM FOLLOW-UP OF TREATMENT-EMERGENT RESISTANCE-ASSOCIATED VARIANTS IN NS3, NS5A AND NS5B WITH PARITAPREVIR/R-, OMBITASVIR- AND DASABUVIR-BASED REGIMENS</td>
<td>Preethi Krishnan (United States)</td>
</tr>
<tr>
<td>16:30</td>
<td>INCREASED CANCER RATES IN PATIENTS WITH CHRONIC HEPATITIS C: AN ANALYSIS OF THE CANCER REGISTRY IN A LARGE U.S. HEALTH MAINTENANCE ORGANIZATION</td>
<td>Anders H. Nyberg (United States)</td>
</tr>
</tbody>
</table>
16:45 - 17:00 Abstract O059: LONG-TERM PERSISTENCE OF HCV NS5A VARIANTS AFTER TREATMENT WITH NS5A INHIBITOR LEDIPASVIR
David Wyles (United States)

17:00 - 17:15 Abstract O060: MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA.
Alessia Piluso (Italy)

17:15 - 17:30 Abstract O061: INCIDENCE OF HEPATITIS C REINFECTION FOLLOWING SUSTAINED Virological RESPONSE – A SEVEN YEAR FOLLOW-UP OF SCANDINAVIAN PATIENTS INFECTED THROUGH INJECTING DRUG USE
Håvard Midgard (Norway)

17:30 - 17:45 Abstract O062: FACTORS ASSOCIATED WITH SPONTANEOUS CLEARANCE OF CHRONIC HEPATITIS C VIRUS INFECTION: A RETROSPECTIVE CASE CONTROL STUDY
Naomi Bulteel (United Kingdom)

17:45 - 18:00 Abstract O063: HCV REINFECTION CASES IN PHASE 3 STUDIES OF SOFOSBUVIR
Evguenia Svarovskaia (United States)

Parallel Session: Cirrhosis and Complications 1
Hall C (Plenary)

Chair:
Aleksander Krag (Denmark)
Candid Villanueva

16:00 - 16:15 Abstract O072: STATIN USE SIGNIFICANTLY DECREASES DECOMPENSATION AND DEATH IN VETERANS WITH HEPATITIS C-RELATED COMPENSATED CIRRHOSIS
Arpan Mohanty (United States)

16:15 - 16:30 Abstract O073: NON-SELECTIVE BETA-BLOCKERS AND MORTALITY IN CIRRHOSIS PATIENTS WITH OR WITHOUT REFRACTORY ASCITES: POST HOC ANALYSIS OF THREE LARGE RCT’S WITH 1198 PATIENTS
Lars Bossen (Denmark)

16:30 - 16:45 Abstract O074: A METABOLOMICS STUDY OF SERUM FROM PATIENTS WITH CIRRHOSIS IDENTIFIES 2 METABOLITES THAT ACCURATELY PREDICT THE ACUTE HVPG RESPONSE TO B-BLOCKER THERAPY
Enric Revei (Spain)

16:45 - 17:00 Abstract O075: ASSESSMENT OF THE TRANSJUGULAR PORTO-SYSTEMIC SHUNT (TIPSS) IN THE MANAGEMENT OF COMPLICATIONS OF NONCIRRHOTIC PORTAL HYPERTENSION
Julien Bissonnette (France)

17:00 - 17:15 Abstract O076: CARDIAC VOLUME OVERLOAD AND PULMONARY HYPERTENSION AFTER LONG-TERM FOLLOW-UP IN TIPS PATIENTS
Theresa A. Hippchen (Germany)

17:15 - 17:30 Abstract O077: USE OF DIRECT ORAL ANTICOAGULANTS (DOACS) IN PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS AND/OR CIRRHOSIS
Andrea De Gottardi (Switzerland)

17:30 - 17:45 Abstract O078: THE PREVALENCE AND MORTALITY OF ACUTE-ON-CHRONIC LIVER FAILURE DEFINED BY APASL VS. EASL-CLIF CONSORTIUM: A MULTICENTER, RETROSPECTIVE COHORT STUDY IN KOREA (KACLIF STUDY)
Do Seon Song (Korea, South)

17:45 - 18:00 Abstract O079: CALR SOMATIC MUTATIONS IN A PROSPECTIVE COHORT OF 308 PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS
Pierre-Emmanuel Rautou (France)
Parallel Session: Autoimmune and genetic liver disease

Strauss 1

Chair:
Ulrich Beuers (Netherlands)
Tom Karlsen (Norway)

16:00 - 16:15 Abstract O080: EARLY CLINICAL FEATURES ASSOCIATED WITH LONG-TERM RISK OF TRANSPLANTATION IN PRIMARY SCLEROSING CHOLANGITIS: RESULTS FROM THE UK-PSC CONSORTIUM
Elizabeth C. Goode (United Kingdom)

16:15 - 16:30 Abstract O081: VAP-1 IS ELEVATED IN PSC, CORRELATES WITH CLINICAL OUTCOME AND EXHIBITS AMINE OXIDASE ACTIVITY IN A SUBSTRATE-DEPENDENT MANNER.
Palak J. Trivedi (United Kingdom)

16:30 - 16:45 Abstract O082: THE GUT MICROBIOTA IN PRIMARY SCLEROSING CHOLANGITIS DIFFERS FROM THAT OF HEALTHY CONTROLS AND ULCELERATIVE COLITIS PATIENTS WITHOUT BILIARY DISEASE
Martin Kummen (Norway)

16:45 - 17:00 Abstract O083: ABSENCE OF BSEP/ABCB11 PROTECTS FROM CHOLESTATIC LIVER AND BILE DUCT INJURY IN A MOUSE MODEL OF SCLEROSING CHOLANGITIS
Claudia D. Fuchs (Austria)

17:00 - 17:15 Abstract O084: NOVEL TREATMENT OPTIONS TO IMPROVE ABERRANT PRE-MESSENGER RNA SPICING AND PROTEIN FOLDING IN ATP8B1 DEFICIENCY
Wendy van der Woerd (Netherlands)

17:15 - 17:30 Abstract O085: LANREOTIDE REDUCES LIVER VOLUME YET ACCELERATES MUSCLE WASTING AND WEIGHT LOSS IN SYMPTOMATIC POLYCYSTIC LIVER DISEASE
Frederik Temmerman (Belgium)

17:30 - 17:45 Abstract O086: BUDESONIDE FOR AUTOIMMUNE HEPATITIS: RESPONSE RATE AND LIMITATIONS IN A LARGE REAL LIFE COHORT
Moritz Peiseler (Germany)

17:45 - 18:00 Abstract O087: IGG4+ B-CELL RECEPTOR CLONES IN PERIPHERAL BLOOD DISTINGUISH IGG4-ASSOCIATED CHOLANGITIS/AUTOIMMUNE PANCREATITIS FROM PRIMARY SCLEROSING CHOLANGITIS
Lowiek M. Hubers (Netherlands)

Parallel Session: Fatty liver disease: experimental

Strauss 2

Chair:
Wim Laleman (Belgium)
Michael Trauner (Austria)

16:00 - 16:15 Abstract O064: GUT-LIVER AXIS DERANGEMENT DUE TO LACK OF INFLAMMASOME ACTIVITY LEADS TO VISCERAL OBESITY AND NASH DEVELOPMENT
Laura Agostinelli (Italy)

16:15 - 16:30 Abstract O065: MECHANISTIC STUDY OF TM6SF2 IN NAFLD PATHOGENESIS: STABLY TRANSFECTED HUH7 CELLS OVER-EXPRESSING THE TM6SF2 E167K VARIANT EXHIBIT GREATER LEVELS OF OXIDATIVE STRESS
Quentin M. Anstee (United Kingdom)
16:30 - 16:45 Abstract O066: BCL-3 REGULATES HEPATIC GLUCOSE AND LIPID METABOLISMS THROUGH INSULIN AND ASSOCIATED METABOLIC TRANSCRIPTION FACTORS Nadine Gehrke (Germany)

16:45 - 17:00 Abstract O067: HEMATOPOIETIC OVEREXPRESSION OF CYP27A1 REDUCES HEPATIC INFLAMMATION INDEPENDENTLY OF 27-HYDROXYCHOLESTEROL LEVELS IN LDLR-/ mice via NPC-MODULATED CHOLESTEROL TRANSPORT Tim Hendrikx (Belgium)

17:00 - 17:15 Abstract O068: LYSOSOMAL CHOLESTEROL IN KUPFFER CELLS, PARTICULARLY WHEN OXIDIZED, CONTRIBUTES TO MURINE STEATOHEPATITIS Sofie Walenbergh (Netherlands)

17:15 - 17:30 Abstract O069: EVIDENCE FOR A ROLE OF CCR2 IN HUMAN NON-ALCOHOLIC FATTY LIVER DISEASE Richard Parker (United Kingdom)

17:30 - 17:45 Abstract O070: CX3CR1 IS A GATEKEEPER FOR INTESTINAL BARRIER INTEGRITY: LIMITING STEATOHEPATITIS BY PROMOTING INTESTINAL HOMEOSTASIS Kai M. Schneider (Germany)

17:45 - 18:00 Abstract O071: TELOMERASE REVERSE TRANSCRIPTASE MUTATIONS ARE ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN NASH Benedetta Donati (Italy)

Parallel Session: Liver tumours: Clinical
Lehar 1 & 2

Chair:
Helen Reeves (United Kingdom)
Wolfgang Sieghart (Austria)

16:00 - 16:15 Abstract TBD

16:15 - 16:30 Abstract O049: SERUM LIPIDOMIC PROFILING FOR SCREENING POTENTIAL BIOMARKERS OF HEPATOCELLULAR CARCINOMA BY ULTRAPERFORMANCE LIQUID CHROMATOGRAPHY–MASS SPECTROMETRY Ana Maria Passos-Castilho (Brazil)

16:30 - 16:45 Abstract O050: A NEW ALGORITHM FOR PREDICTING THE HEPATOCELLULAR CARCINOMA OCCURRENCE IN CIRRHOTIC PATIENTS Simona Bota (Austria)

16:45 - 17:00 Abstract O051: SOX9 IS A NOVEL CANCER STEM CELL MARKER SURROGATED BY OSTEOPONTIN IN HUMAN HEPATOCELLULAR CARCINOMA Takayuki Kawai (Japan)

17:00 - 17:15 Abstract O052: ASSESSMENT OF THE HONG KONG LIVER CANCER STAGING SYSTEM IN EUROPE Philippe Kolly (Switzerland)

17:15 - 17:30 Abstract O053: GALNT14 GENOTYPE INDEPENDENTLY PREDICTS COMPLETE THERAPEUTIC RESPONSES OF TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA Chau-Ting Yeh (Taiwan)

17:30 - 17:45 Abstract O054: TM6SF2-T AND PNPLA3-G GENETIC VARIANTS CO-MODULATE THE RISK OF HEPATOCELLULAR CARCINOMA IN CAUCASIAN PATIENTS WITH ALCOHOLIC CIRRHOSIS. INTER-COHORT VALIDATION IN 1068 PATIENTS. Pierre Nahon (France)
17:45 - 18:00 | Abstract O055: PUSHING THE LIMITS FOR TACE: SELECTION FOR TRANSARTERIAL CHEMOEMBOLISATION TREATMENT (STATE) SCORE IDENTIFIES HCC PATIENTS AT BCLC STAGE C SUITABLE FOR TACE
Florian Hucke (Austria)

Recent Highlights from the Literature: Ask the Authors
Stolz 1

Chair:
Frank Lammert (Germany)

Abdominal Sonography Course- Advanced
Lehar 3

Tutors:
Robert de Knecht (Netherlands)
Michael Gebel (Germany)
Andrei Potthoff (Germany)
Dave Sprengers (Netherlands)
Pavel Taimr (Netherlands)
Christoph Terkamp (Germany)

18:30 – 20:00

Major Sponsor Industry Satellite Symposium

18:30 - 20:00 | Please refer to the Industry Section
Saturday, April 25, 2015

Industry Satellite Symposium

7:30 - 8:30 Please refer to the Industry Section

General Session 3 & Award 2
Hall D

Chair:
Mauro Bernardi (Italy)
A.Kadir Dokmeci (Turkey)

08:30 - 08:45 Abstract G13: OMBITASVIR/PARITAPREVIR/RITONAVIR FOR TREATMENT OF HCV GENOTYPE 1B IN JAPANESE PATIENTS WITH OR WITHOUT CIRRHOSIS: RESULTS FROM GIFT-I
Lino Rodrigues-Jr. (United States)

08:45 - 09:00 Abstract G14: SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) IS A MAJOR DETERMINANT OF TREATMENT RESPONSE TO TERLIPRESSIN FOR HEPATORENAL SYNDROME TYPE 1 (HRS-1)
Florence Wong (Canada)

09:00 - 09:15 Abstract G18: THE FXR AGONIST PX20606 REDUCES LIVER DAMAGE, FIBROSIS AND PORTAL HYPERTENSION IN CIRRHOTIC RATS
Philipp Schwabl (Austria)

09:15 - 09:45 Award Ceremony II

09:45 - 10:00 Abstract G16: THE COLFOUNDING ROLE OF SEVERE COMORBIDITIES AND ALCOHOL USE DISORDERS ON PROGNOSIS IN CHRONIC HEPATITIS C VIRUS INFECTION: AN ANALYSIS OF THE 2008-2012 FRENCH NATIONAL HOSPITAL DISCHARGE DATABASE
Michaël Schwarzinger (France)

10:00 - 10:15 Abstract G17: A DISTINCT PROFILE OF LYSO-PHOSPHATIDYLCHOLINES AND AMINO ACIDS CHARACTERIZES NAFLD IN LEAN SUBJECTS
Alexandra Feldman (Austria)

10:15 - 10:30 Abstract G15: THE ASSOCIATION OF SOFOSBUVIR AND DACLATASVIR FOR TREATING SEVERE RECURRENCE OF HCV INFECTION AFTER LIVER TRANSPLANTATION: RESULTS FROM A LARGE FRENCH PROSPECTIVE MULTICENTRIC ANRS CO23 CUPILT COHORT
Audrey Coilly (France)

State of the Art Session - Basic Science
Hall D

Speaker:
Rakesh Jain (United States)

10:30 - 11:00 Reengineering the microenvironment to improve treatment of fibrotic diseases
Basic Symposium - Metabolic Disorders: Metabolism and cancer: the circadian clock connection

Chair:
Selma Masri (United States)

14:00 - 14:30 Partitioning of circadian metabolism in the liver
Speaker: Selma Masri (United States)

14:30 - 15:00 Role of SIRT1 in liver regeneration
Speaker: Marina Bellet (Italy)

15:00 - 15:30 High-throughput analysis of circadian liver gene expression
Speaker: Frederic Gachon (Switzerland)

Parallel Session: Cirrhosis and Complications 2
Hall D

Chair:
Shiv K. Sarin (India)
Dominique Thabut (France)

11:30 - 11:45 Abstract O088: HIGH-THROUGHPUT SEQUENCING OF THE HUMAN HEPATIC PROGENITOR CELL NICHE REVEALS DIFFERENT SIGNALLING PATHWAYS DEPENDING ON THE UNDERLYING CHRONIC LIVER DISEASE
Olivier Govaere (Belgium)

11:45 - 12:00 Abstract O089: INCREASED NEURONAL EXPRESSION OF K-TYPE GLUTAMINASE POTENTIATES BRAIN EDEMA IN ACUTE LIVER FAILURE MICE THROUGH A TLR4 DEPENDENT PATHWAY
Yalda Sharifi (United Kingdom)

12:00 - 12:15 Abstract O090: HUMANIZATION OF GERM-FREE MICE WITH ALCOHOLIC CIRRHOTIC MICROBIOTA, BUT NOT HEALTHY MICROBIOTA, INDUCES BACTERIAL TRANSLOCATION AND A PRO-INFLAMMATORY MILIEU, WHICH IS AMELIORATED WITH LACTOBACILLUS GG
Jasmohan S. Bajaj (United States)

12:15 - 12:30 Abstract O091: ORAL THERAPY WITH NON-ABSORBABLE CARBONS OF CONTROLLED POROSITY (YAQ-001) SELECTIVELY MODULATES STOOL MICROBIOME AND ITS FUNCTION AND THIS IS ASSOCIATED RESTORATION OF IMMUNE FUNCTION AND INFLAMMASOME ACTIVATION
Jane Macnaughtan (United Kingdom)

12:30 - 12:45 Abstract O092: MICROBIOLOGICAL ASSESSMENT OF ASCITIC FLUID IN LIVER DISEASE: CULTURE TECHNIQUES, SENSITIVITIES AND INTERPRETATION
Presenter: Diarmid Sutherland (United Kingdom)

12:45 - 13:00 Abstract O093: THE EMPIRICAL ANTIBIOTIC TREATMENT OF NOSOCOMIAL SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS: RESULTS OF A RANDOMIZED CONTROLLED CLINICAL TRIAL
Salvatore Piano (Italy)

13:00 - 13:15 Abstract O094: THE PRESENCE OF ECHOCARDIOGRAPHIC ABNORMALITIES INCREASES MORTALITY IN PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS
Mattias Mandorfer (Austria)
Parallel Session: EU and Public Health
Hall C (Plenary)

Chair: David Goldberg (United Kingdom)

11:30 - 11:45 Abstract O120: ADVANCED FIBROSIS IS COMMON IN INDIVIDUALS WHOSE HEPATITIS C HAS NOT BEEN DIAGNOSED: RESULTS FROM THE NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY 2001-2012
Prowpanga Udompap (United States)

11:45 - 12:00 Abstract O121: THE USE OF A POCKET-SIZED ULTRASOUND DEVICE IMPROVES PHYSICAL EXAMINATION: RESULTS OF AN IN- AND OUTPATIENT STUDY
Agostino Colli (Italy)

12:00 - 12:15 Abstract O122: CLINICAL IMPACT OF FIVE LARGE-SCALE SCREENING PROJECTS FOR CHRONIC HEPATITIS B AND C IN CHINESE MIGRANTS IN THE NETHERLANDS
S. Coenen (Netherlands)

12:15 - 12:30 Abstract O123: TEN YEARS OF HOSPITAL ADMISSIONS FOR LIVER CIRRHOSIS IN PORTUGAL
Mario J. Silva (Portugal)

12:30 - 12:45 Abstract O124: IS INCREASED HCV CASE-FINDING COMBINED WITH 8 OR 12 WEEK INTERFERON-FREE DIRECT-ACTING ANTIVIRAL TREATMENT COST-EFFECTIVE IN UK PRISONS? A COST UTILITY ANALYSIS INCLUDING TREATMENT AS PREVENTION BENEFITS
Natasha K. Martin (United Kingdom)

12:45 - 13:00 Abstract O125: A SYSTEMATIC REVIEW OF HEPATITIS B AND C TESTING IN THE COUNTRIES OF THE WHO EUROPEAN REGION
Jeffrey V. Lazarus (Denmark)

Christophe Ramière (France)

Eva Stein (United States)

Parallel Session: Liver inflammation, regeneration and cancer
Strauss 1

Chair: Tom Luedde (Germany)
Cecilia Rodrigues (Portugal)

11:30 - 11:45 Abstract O096: MATRIX METALLOPROTEINASE-10 CONTRIBUTES TO HEPATOCELLULAR CARCINOMA DEVELOPMENT IN A NOVEL CROSSTALK WITH STROMAL DERIVED GROWTH FACTOR 1/C-X-C CHEMOKINE RECEPTOR 4 AXIS.
Oihane Garcia-Irigoyen (Spain)
11:45 - 12:00 Abstract O097: MUTATION OF RELA THR505 ENHANCES LIVER REGENERATION FOLLOWING PARTIAL HEPATECTOMY
Anna Moles (United Kingdom)

12:00 - 12:15 Abstract O098: LONG TERM NLRP3 INFLAMMASOME ACTIVATION LEADS TO SEVERE LIVER FIBROSIS VIA INFLAMMATORY MACROPHAGE POLARIZATION AND DIRECT ACTIVATION OF HEPATIC STELLATE CELLS
Alexander Wree (United States)

12:15 - 12:30 Abstract O099: CYSTEINE CATHEPSINS CONTROL LIVER INFLAMMATION THROUGH REGULATION OF SIRTUIN-1 ACTION ON P65-NFκB SUBUNIT
Alvaro de Mingo (Spain)

12:30 - 12:45 Abstract O100: THE HEPATIC MICROENVIRONMENT INDUCES A CSC PHENOTYPE AND DETERMINES THE PROGNOSIS OF HCC PATIENTS
Darko Castven (Germany)

12:45 - 13:00 Abstract O101: HISTONE VARIANT MACROH2A1 ORCHESTRATES ESCAPE FROM HEPATOCELLULAR CARCINOMA DURING AGEING AND CANCER.
Michela Borghesan (United Kingdom)

13:00 - 13:15 Abstract O102: GALECTIN-1 EXPRESSION IS ESSENTIAL FOR AN EFFECTIVE LIVER REGENERATION
Eithan Galun (Israel)

13:15 - 13:30 Abstract O103: METASTASIS DEVELOPMENT IN A NOVEL MOUSE MODEL OF ADVANCED LIVER CANCER
Ursula Ehmer (Germany)

Parallel Session: Liver Transplantation
Strassu 2

Chair:
Gabriela Berlakovich
Patrizia Burra (Italy)

11:30 - 11:45 Abstract O104: PREDICTIVE MODEL FOR THE NEED FOR LIVER TRANSPLANTATION IN SYMPTOMATIC POLYCYSTIC LIVER DISEASE
Frederik Temmerman (Belgium)

11:45 - 12:00 Abstract O105: COMPARISON OF SHORT-TERM AND LONG-TERM OUTCOMES AFTER DCD AND DBD DONOR LIVER TRANSPLANTATION
Wayel Jassem (United Kingdom)

12:00 - 12:15 Abstract O106: THERAPEUTIC PLASMA EXCHANGE MODULATES INNATE IMMUNE ACTIVATION AND IMPROVES OUTCOME IN PATIENTS WITH ACUTE LIVER FAILURE
Christine Bernsmeier (United Kingdom)

12:15 - 12:30 Abstract O107: IL-22 SECRETION IS REQUIRED FOR LIVER REGENERATION AND IS MODULATED BY EXTRACELLULAR NUCLEOTIDES
Guido Beldi (Switzerland)

12:30 - 12:45 Abstract O108: RESIDUAL HCV-RNA IN LIVER EXPLANTS FROM PATIENTS UNDERGOING SOFOSBUVIR AND RIBAVIRIN TREATMENT WHILE WAITING LIVER TRANSPLANTATION IS NOT ASSOCIATED WITH HCV RELAPSE
Martina Gambato (Spain)
Georges-Philippe Pageaux (France)

13:00 - 13:15 Abstract O110: SIMEPREVIR + SOFOSBUVIR COMBINATION THERAPY FOR RECURRENT GENOTYPE-1 HEPATITIS C IN LIVER TRANSPLANT RECIPIENTS: A REAL-LIFE MULTICENTER EXPERIENCE
Helen Te (United States)

Elmar Jaeckel (Germany)

Parallel Session: Viral Hepatitis B & D: Clinical
Strauss 3

Chair:
Jerzy Jaroszewicz (Poland)
Cihan Yurdaydin (Turkey)

11:30 - 11:45 Abstract O112: HBSAG CLEARANCE AFTER ADDITION OF 48 WEEKS OF PEGIFN IN HBEAG NEGATIVE CHB PATIENTS ON NUCLEOS(T)IDE THERAPY WITH UNDETECTABLE HBV DNA FOR AT LEAST ONE YEAR: FINAL RESULTS FROM ANRS-HB06 PEGAN STUDY: MULTICENTER RANDOMIZED CONTROLLED PHASE III TRIAL
Marc Bourliere (France)

11:45 - 12:00 Abstract O113: HLA DPB1 RS9277535 POLYMORPHISM STRONGLY PREDICTS HBSAG CLEARANCE IN IFN TREATED GENOTYPE D HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B
Pietro Lampertico (Italy)

12:00 - 12:15 Abstract O114: SERUM HBV-RNA LEVELS DECLINE SIGNIFICANTLY IN CHRONIC HEPATITIS B PATIENTS DOSED WITH THE NUCLEIC-ACID POLYMER REP2139-CA
Louis Jansen (Netherlands)

12:15 - 12:30 Abstract O115: HIGH ANTIVIRAL ACTIVITY OF THE HBV CORE INHIBITOR NVR 3-778 IN THE HUMANIZED UPA/SCID MOUSE MODEL
Klaus Klumpp (United States)

12:30 - 12:45 Abstract O116: PREDICTIVE VALUE OF BASELINE AND ON-TREATMENT QHBGSAG LEVEL IN HBEAG POSITIVE CHB PATIENTS WHO SWITCHED FROM NUCS TO PEGYLATED INTERFERON A-2A: A FURTHER ANALYSIS FROM NEW SWITH STUDY
Hong Ren (China)

12:45 - 13:00 Abstract O117: PREDICTORS OF CLINICAL RESPONSE: RESULTS FROM A LARGE, RANDOMIZED CONTROLLED STUDY WITH TENOFVIR DISOPROXIL FUMARATE (TDF) PLUS PEGINTERFERON ALFA-2A (PEG) COMBINATION FOR CHRONIC HEPATITIS B (CHB)
Henry L. Chan (China)

13:00 - 13:15 Abstract O118: OPTIMIZING THE PRENYLATION INHIBITOR LONAFARNIB USING RITONAVIR BOOSTING IN PATIENTS WITH CHRONIC DELTA HEPATITIS.
Cihan Yurdaydin (Turkey)
13:15 - 13:30 Abstract O119: STOPPING TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AFTER LONG TERM VIROLOGIC SUPPRESSION IN HBV-NEGATIVE CHB: WEEK 48 INTERIM RESULTS FROM AN ONGOING RANDOMIZED, CONTROLLED TRIAL (“FINITE CHB”) Thomas Berg (Germany)

**ePoster Oral Sessions**

**Hall B (ePoster Area)**

13:00 – 14:00

| Oral ePoster 1 | Molecular and cellular biology | Catherine Postic (France) |
| Oral ePoster 2 | Transplantation and acute liver failure | Giacomo Germani (Italy) |
| Oral ePoster 3 | Liver fibrosis, Nanomedicine and new technologies | Klaas Poelstra (Netherlands) |
| Oral ePoster 4 | Autoimmune liver disease | Marco Marzioni (Italy) |

**Clinical Symposium - Future of HBV treatments**

**Hall D**

Chair: Fabien Zoulim (France)

14:00 - 14:20 The current treatment situation and definitions of a cure for chronic HBV infection Goefrey Dusheiko (United Kingdom)
14:20 - 14:40 The main unresolved questions to cure HBV infection Ulrike Protzer (Germany)
14:40 - 15:00 The new direct antivirals in pre-clinical and early clinical development Fabien Zoulim (France)
15:00 - 15:30 Novel concepts of immune therapy (restoration of innate and/or adaptive immune responses) Antonio Bertoletti (Singapore)

**Basic Symposium - Metabolic Disorders: Metabolism and cancer: the circadian clock connection**

**Hall C (Plenary)**

Chair: Selma Masri (United States)

14:00 - 14:30 Partitioning of circadian metabolism in the liver Selma Masri (United States)
14:30 - 15:00 Role of SIRT1 in liver regeneration Marina Bellet (Italy)
15:00 - 15:30 High-throughput analysis of circadian liver gene expression Frederic Gachon (Switzerland)
Clinical Symposium - Treatment decisions in intermediate stage HCC

Strauss 1

Chair: Jens Ricke (Germany)

14:00 - 14:05 A critical appraisal of where we are in the intermediate stage today
Jens Ricke (Germany)

14:05 - 14:30 How to determine the appropriate TACE candidate and when to time the next intervention
Wolfgang Sieghart (Austria)

14:30 - 15:00 Is there a role of combination treatments today – arguments and evidence for the combined or sequential use of the current toolbox
Maciej Pech (Germany)

15:00 - 15:30 Where is the place for Y90-radioembolization today?
Bruno Sangro (Spain)

Clinical Symposium - Bacterial infections in patients with liver disease

Strauss 2

Chair: Javier Fernandez (Spain)

14:00 - 14:05 Introduction
Javier Fernandez (Spain)

14:05 - 14:30 Advances in the pathogenesis and diagnosis of bacterial infections in cirrhosis
Reiner Wiest (Switzerland)

14:30 - 14:55 Multiresistant bacterial infections: mechanisms of resistance, prevention strategies and clinical implications
Alex Soriano (Spain)

Thierry Gustot (Belgium)

15:20 - 15:30 Discussion

WHO-EASL Symposium

Strauss 3

Chair: Markus Peck-Radosavljevic (Austria)
Stefan Wiktor (Switzerland)

14:00 - 14:15 WHO Prequalification of hepatitis serologic tests - A review of the results of the analysis of the performance of hepatitis B and C rapid and enzyme immunoassay tests and assessment of manufacturers’ production quality
Anita Sands (Switzerland)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:15 - 14:30 | Cost-effectiveness analysis of screening – NICE UK example. An economic analysis of risk-based screening for hepatitis B  
Natasha Martin (United Kingdom) |
| 14:30 - 14:45 | Providing testing services for persons who inject drugs and linking them to care – Scottish example  
David Goldberg (United Kingdom) |
| 14:45 - 15:00 | Implementing the birth-cohort approach to hepatitis C testing – the US example  
John Ward (United States) |
| 15:00 - 15:15 | Providing hepatitis testing services to persons with HIV infection in low- and middle-income countries – the MSF experience  
Isabelle Andrieux-Meyer (Switzerland) |
| 15:15 - 15:30 | WHO recommendations on screening and testing  
Philippa Easterbrook (Switzerland) |

Young Investigator Forum
Lehar 1 & 2

Chair:
Giacomo Germani (Italy)  
Helen Reeves (United Kingdom)

14:00 - 14:05 | Who are the YI CAG?  
Giacomo Germani (Italy) |
14:05 - 14:20 | How to publish in top journals: do’s and don’t  
Rajiv Jalan (United Kingdom) |
14:20 - 14:35 | How you are evaluated for positions and grants (talk about bibliometrics, points to be emphasized in the CV)  
Helen Reeves (United Kingdom) |
14:35 - 14:50 | How to make an effective presentation  
Alessio Aghemo (Italy) |
14:50 - 15:05 | Research in hepatology: past, present and future  
Speaker:  
Jean-Michel Pawlotsky (France) |
15:05 - 15:15 | YI Awardee Presentation 1 |
15:15 - 15:25 | YI Awardee Presentation 2 |
15:25 - 15:30 | Discussion |

Joint Workshop: EASL-JHS
Stolz 2

Chairs:
TBD
14:00 – 15:30
Late Breakers

Hall D

Chairs:
TBD

16:00 - 18:00 | TBD

EASL Business Meeting

Lehar 4

18:15 - 19:30 | Access restricted to active EASL members

Abdominal Sonography Course- ‘Acute Medicine’ in Hepatology

Lehar 3

Tutors:
Robert de Knegt (Netherlands)
Michael Gebel (Germany)
Andrej Potthoff (Germany)
Dave Sprengers (Netherlands)
Pavel Taimr (Netherlands)
Christoph Terkamp (Germany)

18:30 – 20:00 |
Sunday, April 26, 2015

Early Morning Workshops

Towards ultrashort treatments for HCV
Hall C (Plenary)

Moderators:
  Graham Foster (United Kingdom)
  Christophe Hezode (France)

7:30 - 8:30

Public health and viral hepatitis: what can we do to reduce the future burden of disease?
Strauss 1

Moderators:
  Sylvie Deuffic-Burban (France)
  Magda Rosinka (Poland)

7:30 - 8:30

Diagnosis and Treatment of chronic HDV infection
Strauss 2

Moderators:
  Ramazan Idilman (Turkey)
  Heiner Wedemeyer (Germany)

7:30 - 8:30

New oral anticoagulants in patients with liver disease
Strauss 3

Moderators:
  Andres de Gottardi (Switzerland)
  Fuat Saner (Germany)

7:30 - 8:30
Interventional strategies in patients with portal hypertension

Lehar 1 & 2

Moderators:
- Roberto de Francis (Italy)
- Arnulf Ferlitsch (Austria)
- Andres Cardenas (Spain)

7:30 - 8:30

Update on classification and management of liver adenomas

Lehar 3

Moderators:
- Olivier Farges (France)
- Peter Schirmacher (Germany)

7:30 - 8:30

Study design in gut microbiome assessments

Lehar 4

Moderators:
- Antonio Gasbarinni (Italy)
- Herbert Tilg (Austria)

7:30 - 8:30

Animal models of liver fibrosis

Stolz 1

Moderators:
- Rabea Hall (Germany)
- Fiona Oakley (United Kingdom)

7:30 - 8:30

Metabolomic technologies and applications in liver disease

Stolz 2

Moderators:
- Jeff Idle (Switzerland)
- José Matos (Spain)

7:30 - 8:30
Fatigue in chronic liver disease
Schubert 1

Moderators:
David Jones (United Kingdom)
Aleksander Krag (Denmark)

7:30 - 8:30

Acute on chronic liver failure: new definitions
Schubert 2

Moderators:
Javier Fernandez (Spain)
Claire Francoz (France)

7:30 - 8:30

Antiviral Therapy in HIV-HCV coinfected patients
Schubert 4

Moderators:
Raffael Bruno (Italy)
Mattias Mandorfer (Austria)

7:30 - 8:30

Antibody-mediated rejection after liver transplantation: practical implications
Schubert 5

Moderators:
Daniel Gotthardt (Germany)
Desley Neil (United Kingdom)

7:30 - 8:30

Immunosuppression after OLT in PSC
Schubert 6

Moderators:
Kirsten M. Boberg (Norway)
Christian Strassburg (Germany)

7:30 - 8:30
Major Sponsor Industry Satellite Symposium

8:30 - 10:00

Please refer to the Industry Section

30 yrs of Journal of Hepatology: Emerging issues in Hepatology
Hall C (Plenary)

Chair:
Rajiv Jalan (United Kingdom), Markus Peck-Radosavljevic (Austria)

08:30 - 08:35 Introduction to the Session
Rajiv Jalan (United Kingdom)

08:35 - 08:50 Alcoholic and non-alcoholic fatty liver disease
Ramon Bataller (Spain)

08:50 - 09:05 Cirrhosis and Liver Failure
Richard MOREAU (France)

09:05 - 09:20 Liver Cancer
Jessica Zucman Rossi (France)

09:20 - 09:35 Viral Hepatitis
Thomas Berg (Germany)

09:35 - 10:00 Panel Discussion
Moderators:
Rajiv Jalan (United Kingdom), Markus Peck-Radosavljevic (Austria)
Panelist:
Vicente Arroyo (Spain), Massimo Colombo (Italy), Pere Gines (Spain), Gustav Paumgartner (Germany), Didier Samuel (France), Roger Williams (United Kingdom)

Basic Symposium - Liver stem cells
Hall C (plenary)

Chair:
Tamir Rashid (France)

10:00 - 10:50 Regenerative approaches through developmental biology
Takanori Takebe (Japan)

10:50 - 11:10 Regenerative approaches through endogenous targets
Stuart Forbes (United Kingdom)

11:10 - 11:30 Regenerative approaches through tissue engineering
Suchitra Sumitran-Holgersson (Sweden)
Clinical Symposium - Multidisciplinary management of alcoholic liver disease

Strauss 1

Chair: Giovanni Addolorato (Italy)

10:00 - 10:50 Management strategies in patients with alcoholic Liver disease
Chris Day (United Kingdom)

10:50 - 11:10 Management of alcohol dependence in patients with alcoholic liver disease
Lorenzo Leggio (United States)

11:10 - 11:30 Liver transplantation in patients with alcoholic liver disease
Philippe Mathurin (France)

Clinical Symposium - Liver disease management in Eastern Europe

Strauss 2

Chair: Jerzy Jaroszewicz (Poland)

10:00 - 10:50 Current trends in hepatitis B epidemiology and prevention in CEE
Speaker: Liana Gheorghe (Romania)

10:50 - 11:05 Current trends in hepatitis C epidemiology and prevention in CEE
Speaker: Robert Flisiak (Poland)

11:05 - 11:20 Access to novel therapies and possible strategy for countries with limited resources
Speaker: Béla Hunyady (Hungary)

11:20 - 11:30 Discussion

Clinical Symposium - Re-focusing transplant hepatology

Strauss 3

Chair: François Durand (France)

10:00 - 10:50 The decline of immunology in liver transplantation: for how long?
François Durand (France)

10:50 - 11:10 Changes in the management of HCV-infected patients, pre and post transplantation
Adrian C. Gadano (Argentina)

11:10 - 11:30 Reconsidering alternatives to transplantation for hepatocellular carcinoma in the context of organ shortage
Massimo Colombo (Italy)
Clinical Symposium - Value-Based Medicine in Hepatology
Lehar 1 & 2

Chair:
Mario Strazzabosco (Italy)

10:00 - 10:50 Value and outcome in delivering healthcare
Paul Kind (United Kingdom)

10:50 - 11:10 What is Value in Health Care: how physicians can change the future of Health
Jens Deerberg-Wittram (Germany)

11:10 - 11:30 Generation and validation of outcome measurements for the main liver diseases
Mario Strazzabosco (Italy)

General Session 4 & Closing

Hall C (Plenary)

Chair:
Jean-François Dufour (Switzerland)
Cihan Yurdaydin (Turkey)

11:30 - 12:00 NAFLD, Metabolic and Genetics
Giulio Marchesini

12:00 - 12:30 Complications of Cirrhosis/HCC
Dominique-Charles Valla (France)

12:30 - 13:00 Viral hepatitis
Michael Manns (Germany)